Iovance Biotherapeutics Inc. IOVA stock has declined by 29.92% in pre-market trading. This comes after the company reported its second-quarter financial results.
Check out the current price of IOVA stock here.
What Happened: The stock of the California-based biotechnology company was trading at $2.64, up by $0.60 on Thursday, according to the Benzinga Pro data. However, this rise was followed by a dip, dropping the share price to $1.85.
The dip in the stock was due to the release of Lovance’s second-quarter financial results and corporate updates. The company reported a 93% year-over-year increase in revenue for the second quarter of 2025, with a total product revenue of $60 million from Amtagvi and Proleukin. This marked a significant jump from the $31.1 million reported in the second quarter of 2024.
U.S. Amtagvi product revenue alone reached $54.1 million from treating 102 patients, driven by increased activity at both existing and new treatment centers.
See Also: Avalanche Up 7% On The Day, Part Of Former White House Staff Portfolio: ‘High-Quality Great Core Asset’
The company’s Amtagvi revenue for the second quarter of 2025 was $54.1 million, reflecting the treatment of 102 commercial patients with an objective response rate (ORR) of 48.8%.
Iovance also plans to cut about 19% of its workforce in the upcoming quarter as part of a broader restructuring effort to reduce costs and improve operations, as its valuation has collapsed from around $4.4 billion to its current level.
Why It Matters: The company’s stock performance is a reflection of investor sentiment following the release of its second-quarter financial results and layoff information. The company also reiterated its full-year 2025 total product revenue guidance to $250-$300 million.
Benzinga Edge Stock Rankings indicate that IOVA stock has a negative price trend across all time frames. Track the performance of other players in this segment.
Read Next:
Photo courtesy: khunkornStudio via Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.